VWF/FVIII complex and the management of patient with inhibitors: From laboratory to clinical practice

Haemophilia

Volumn 13, Issue SUPPL. 5, 2007, Pages 69-72

  Berntorp, Eric ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bypass therapy; Factor concentrate; Haemophilia; Inhibitor; Von Willebrand factor

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; FANDHI; HAEMATE; HAEMOFIL M; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANTIGEN PRESENTING CELL; ARTICLE; BLEEDING; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; HEMOPHILIA A; HEMOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; PRIORITY JOURNAL;

BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; COAGULANTS; FACTOR VIII; HEMOPHILIA A; HUMANS; ISOANTIBODIES; THROMBIN; VON WILLEBRAND FACTOR;

EID: 37149039173     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01577.x     Document Type: Article

References (20)

1. White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
2. Courter S, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Seminars in hematology. 2001; 38: 52-9.
3. Lusher J, Abildgaard C, Arkin S, Mannucci P, Zimmerman R, Schwartz L, Hurst D. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: Final report on a hallmark clinical investigation. J Thromb Haemost. 2004; 2: 574-83.
4. Lusher JM, Lee CA, Kessler CM, Bedrosian CL, ReFacto Phase 3 Study Group. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 38-49.
5. Schimpf K, Schwarz P, Kunschak M. Zero incidence of inhibitors in previously untreated patients termediate purity factor VIII concentrate or factor IX complex. Thromb Haemost 1995; 73: 553-5.
6. Yee TT, Pasi KJ, Lilley PA, Lee CA. Actor VIII inhibitors in haemophiliacs: A single-centre experience over 34years, 1964-97. Br J Haematol 1999; 104: 909-14.
7. Ehrenforth S, Kreuz W, Scharrer I et.al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
8. Goudemand J, Rothschild C, Demiguel V et.al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
9. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: The CANAL cohort study. Blood 2007; 108: 4648-4654.
10. Kreuz W, Ettingshausen CE, Auerswald G et.al. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003; 88: EREPO4.
11. Berntorp E, Ekman M, Gunnarsson M, Nilsson IM. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations. Haemophilia 1996; 2: 95-9.
12. Gensana M, Altisent C, Aznar JA et.al. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia 2001; 7: 369-74.
13. Kallas A, Talpsep T. Von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients. Haemophilia 2001; 7: 375-80.
14. Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 1996; 76: 749-54.
15. Astermark J, Voorberg J, Lenk H et.al. Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro. Haemophilia 2003; 9: 567-72.
16. Varadi K, Negrier C, Berntorp E et.al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003; 1: 2374-80.
17. Salvagno GL, Astermark J, Ekman M et.al. Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation. Haemophilia 2007; 13: 51-6.
18. Behrmann M, Pasi J, Saint-Remy JM, Kotitschke R, Kloft M. Von Willebrand factor modulates factor VIII immunogenicity: Comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 2002; 88: 221-9.
19. Dasgupta S, Repesse Y, Bayry J et.al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007; 109: 610-2.
20. Astermark J, Donfield SM, DiMichele DM et.al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: The FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.